As lung cells are killed by the influenza virus, they burst open, releasing molecular signals that trigger the immune cells that can combat the infection. This strategy can be an important red flag that something is wrong; however, if one cell death response, called necroptosis, continues unchecked, it can cause life-threatening injury to lung tissue. In a study published April 10 in the journal Nature, Tufts University School of Medicine scientists and collaborators present a newly developed compound capable of reversing the course of infection in mice by blocking necroptosis.
There are currently few therapeutic options available to reverse the course of a serious flu infection other than to manage symptoms until the body can combat the virus on its own. With prior evidence showing that lung injury can be caused by influenza-induced necroptosis, the researchers showed that a compound called UH15-38 can safely and efficiently block the key receptor in lung cells undergoing necroptosis without intolerable side effects.
Necroptosis is triggered when a cell under duress activates its receptor interacting protein kinase 3 (RIPK3) pathway, thereby attracting immune cells to the area. UH15-38 reduces excessive inflammation by inhibiting the activation of the RIPK3 pathway. Not only did UH15-38 prove to be well-tolerated in mice, but it successfully prevented any influenza deaths, even when administered up to five days into the course of an infection.
The researchers note that if the results from the mouse studies extend into further preclinical and human trials, compounds like UH15-38 could potentially address the most severe flu infections as well as other viruses that trigger severe respiratory symptoms. The value of the approach is how it addresses the inflammation that is intended to be protective but can do more harm than good.
Tufts University researchers helped organize the study and provided key insights into the UH15-38 inhibitor, but these results would not have been possible without investigators at multiple institutions—including Fox Chase Cancer Center, the University of Houston, and St. Jude Children’s Research Hospital—working closely together.
Degterev and his co-collaborators are now pursuing the second generation of these inhibitors. They are also continuing to test how UH15-38 and related compounds can protect against other respiratory diseases. The commercialization of UH15-38 is being managed by Tufts University’s Office for Technology Transfer and Industry Collaboration.
Ioannis Siokas of Tufts Graduate School of Biomedical Sciences and Dingqiang Zhang, formerly of Tufts University School of Medicine, are also authors on the paper.
Complete information on authors, methodology, funders, and conflicts of interest is available in the published paper. The content is solely the responsibility of the authors and does not necessarily represent the official views of the funders. (Newswise/MJ)
